Immunovia Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Jeff Borcherding
Chief executive officer
SEK 6.6m
Total compensation
| CEO salary percentage | 98.30% |
| CEO tenure | 2.1yrs |
| CEO ownership | 0.6% |
| Management average tenure | no data |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -SEK 131m |
| Dec 31 2024 | SEK 7m | SEK 6m | -SEK 77m |
Compensation vs Market: Jeff's total compensation ($USD676.21K) is above average for companies of similar size in the UK market ($USD378.37K).
Compensation vs Earnings: Insufficient data to compare Jeff's compensation with company performance.
CEO
Jeff Borcherding (51 yo)
2.1yrs
Tenure
SEK 6,607,000
Compensation
Mr. Jeff Borcherding served as Chief Executive Officer of US, Immunovia, Inc. at Immunovia AB (publ) since 2022 until April 2023. He serves as Global Chief Executive Officer of Immunovia AB (publ) since Ap...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman | 5yrs | SEK 470.00k | no data | |
| Independent Director | 9.3yrs | SEK 260.00k | no data | |
| Independent Director | no data | no data | no data | |
| Independent Director | 1.5yrs | SEK 212.00k | no data | |
| Independent Director | 1.5yrs | SEK 222.00k | no data | |
| Independent Director | 4yrs | SEK 220.00k | no data |
2.8yrs
Average Tenure
55yo
Average Age
Experienced Board: 0G8X's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 15:20 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immunovia AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Herman Kuntscher | Carlsquare AB |
| Lars Hevreng | Danske Bank |
| Juan Pedro Rodríguez Serrate | Edison Investment Research |